Cargando…

Increased Circulating Betatrophin Concentrations in Patients with Type 2 Diabetes

Betatrophin has recently been described as a key hormone to stimulate beta-cell mass expansion in response to insulin resistance and obesity in mice. The finding has generated an interest in the development of antidiabetic drugs with betatrophin as the active component. However, the circulating leve...

Descripción completa

Detalles Bibliográficos
Autores principales: Espes, Daniel, Martinell, Mats, Carlsson, Per-Ola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055101/
https://www.ncbi.nlm.nih.gov/pubmed/24963292
http://dx.doi.org/10.1155/2014/323407
_version_ 1782320598334046208
author Espes, Daniel
Martinell, Mats
Carlsson, Per-Ola
author_facet Espes, Daniel
Martinell, Mats
Carlsson, Per-Ola
author_sort Espes, Daniel
collection PubMed
description Betatrophin has recently been described as a key hormone to stimulate beta-cell mass expansion in response to insulin resistance and obesity in mice. The finding has generated an interest in the development of antidiabetic drugs with betatrophin as the active component. However, the circulating levels of betatrophin in patients with type 2 diabetes are not well known. Betatrophin concentrations in plasma of 27 type 2 diabetes patients and 18 gender-, age-, and BMI-matched controls were measured. Study participants were characterized with regard to BMI, waist and hip circumference, blood pressure, and fasting plasma blood lipids, creatinine, glucose, HbA1c, and C-peptide. HOMA2 indices were calculated. Betatrophin was 40% higher in patients with type 2 diabetes (893 ± 80 versus 639 ± 66 pg/mL). Betatrophin positively correlated with age in the controls and with HbA1c in the type 2 diabetes patients. All study participants were insulin resistant with mean HOMA2B IR in both groups exceeding 2 and HOMA2%S < 50%. Control individuals had impaired fasting glucose concentrations. In this report on betatrophin concentrations in type 2 diabetes and insulin resistance, elevated betatrophin levels were measured in the patients with type 2 diabetes. Future studies are clearly needed to delineate the exact role, if any, of betatrophin in regulating human beta-cell mass.
format Online
Article
Text
id pubmed-4055101
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-40551012014-06-24 Increased Circulating Betatrophin Concentrations in Patients with Type 2 Diabetes Espes, Daniel Martinell, Mats Carlsson, Per-Ola Int J Endocrinol Research Article Betatrophin has recently been described as a key hormone to stimulate beta-cell mass expansion in response to insulin resistance and obesity in mice. The finding has generated an interest in the development of antidiabetic drugs with betatrophin as the active component. However, the circulating levels of betatrophin in patients with type 2 diabetes are not well known. Betatrophin concentrations in plasma of 27 type 2 diabetes patients and 18 gender-, age-, and BMI-matched controls were measured. Study participants were characterized with regard to BMI, waist and hip circumference, blood pressure, and fasting plasma blood lipids, creatinine, glucose, HbA1c, and C-peptide. HOMA2 indices were calculated. Betatrophin was 40% higher in patients with type 2 diabetes (893 ± 80 versus 639 ± 66 pg/mL). Betatrophin positively correlated with age in the controls and with HbA1c in the type 2 diabetes patients. All study participants were insulin resistant with mean HOMA2B IR in both groups exceeding 2 and HOMA2%S < 50%. Control individuals had impaired fasting glucose concentrations. In this report on betatrophin concentrations in type 2 diabetes and insulin resistance, elevated betatrophin levels were measured in the patients with type 2 diabetes. Future studies are clearly needed to delineate the exact role, if any, of betatrophin in regulating human beta-cell mass. Hindawi Publishing Corporation 2014 2014-05-22 /pmc/articles/PMC4055101/ /pubmed/24963292 http://dx.doi.org/10.1155/2014/323407 Text en Copyright © 2014 Daniel Espes et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Espes, Daniel
Martinell, Mats
Carlsson, Per-Ola
Increased Circulating Betatrophin Concentrations in Patients with Type 2 Diabetes
title Increased Circulating Betatrophin Concentrations in Patients with Type 2 Diabetes
title_full Increased Circulating Betatrophin Concentrations in Patients with Type 2 Diabetes
title_fullStr Increased Circulating Betatrophin Concentrations in Patients with Type 2 Diabetes
title_full_unstemmed Increased Circulating Betatrophin Concentrations in Patients with Type 2 Diabetes
title_short Increased Circulating Betatrophin Concentrations in Patients with Type 2 Diabetes
title_sort increased circulating betatrophin concentrations in patients with type 2 diabetes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055101/
https://www.ncbi.nlm.nih.gov/pubmed/24963292
http://dx.doi.org/10.1155/2014/323407
work_keys_str_mv AT espesdaniel increasedcirculatingbetatrophinconcentrationsinpatientswithtype2diabetes
AT martinellmats increasedcirculatingbetatrophinconcentrationsinpatientswithtype2diabetes
AT carlssonperola increasedcirculatingbetatrophinconcentrationsinpatientswithtype2diabetes